ImmunityBio

This , we come together to raise awareness, support research, and honor the courage of young warriors and their families who face the battle against childhood cancer every day.

Join ImmunityBio's dynamic team to take part in pioneering advancements in cancer and infectious disease prevention and treatment. Explore our here: https://immunitybio.com/careers/

We're excited to attend the San Diego Urological Society's 2024 Meeting. ImmunityBio believes in the power of collaboration and research to advance patient care and improve patient outcomes.

Today, we announced that we are studying ANKTIVA in combination with the investigational AdHER2DC cancer vaccine as a potential treatment for endometrial cancer, aiming to improve outcomes and sustain clinical response. Learn more:

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer - ImmunityBio CULVER CITY, Calif., August 6, 2024 — Immunotherapy company ImmunityBio, Inc. (NASDAQ: IBRX), today announced the opening of a clinical trial to study ANKTIVA® (nogapendekin alfa inbakicept-pmln) together with the investigational AdHER2DC vaccine (autologous dendritic cells transduced with HER2 e...

is a genetic disorder that increases the risk of developing cancers like pancreatic cancer and colorectal cancer. At Immunitybio, we're pursuing that have the potential to outsmart the disease. Read more: https://immunitybio.com/lynch-syndrome/

Today is . At ImmunityBio, we’re pioneering advanced immunotherapy treatments to bolster immune responses and improve outcomes. Together, we can make a difference. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/

According to American Brain Tumor Association, Glioblastomas constitute nearly 14% of all primary brain tumors. Our research aims to improve survival rates and quality of life for patients with . Read more: https://immunitybio.com/glioblastoma/

If you are passionate about our mission to develop innovative therapies that target some of the most difficult-to-treat human diseases, consider joining our expanding team of talented professionals. View our here: https://immunitybio.com/careers/

In the U.S., approximately 12,000 people are diagnosed with annually. On Glioblastoma Awareness Day, ImmunityBio reaffirms our commitment to advancing research for better patient outcomes. Learn more: https://immunitybio.com/glioblastoma/

At ImmunityBio we are revolutionizing cancer and infectious disease treatments with a powerful new approach. Our therapies are designed to do more than today's treatments by boosting the body's own immune response for long-term protection.

Can immunotherapy treat cancer in dogs? The New York Times interviewed ImmunityBio's chief science officer for cellular products (and certified dog lover), Dr. Hans Klingemann to learn more about his personal research into this question. https://www.nytimes.com/2024/06/21/science/dogs-cancer-immunotherapy.html?searchResultPosition=1

Firefighters face high risks every day — and they’re also at a higher risk of developing bladder cancer due to exposure to carcinogens on the job. We salute these everyday heroes — and those who advocate for more research into bladder cancer. Learn more at BCAN: https://bcan.org/find-support/firefighters-and-bladder-cancer/

In case you missed it, earlier today we announced the first NMIBC patients have been treated with commercially available doses of ANKTIVA, less than two months after we received FDA approval for this exciting new therapy. Learn more:

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors - ImmunityBio CULVER CITY, Calif., June 20, 2024 — ImmunityBio, Inc. (NASDAQ: IBRX) today announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA® (nogapendekin alfa inbakicept-pmln), ImmunityBio’s recently approved immunotherapy for Bacillus Calmette-Guérin...

We met with Robin Beth Dubin of http://Aliveandkickn.org, they're doing great work for Lynch syndrome "previvors." We're honored to partner with National Cancer Institute (NCI) on one of two U.S. cancer vaccine studies focused on Lynch syndrome. Learn more at http://AliveandKickin.org and http://Livingwithlynch.org.

aliveandkickin.org

ImmunityBio CEO Rich Adcock and CMO Dr. Bobby Reddy participated in a fireside chat at the annual Jefferies Global Healthcare Conference this week in New York City.

ImmunityBio is happy to support the Society for Immunotherapy of Cancer (SITC’s) annual fundraiser to raise money for cancer research. The Checkpoints, a physician band we sponsored, played at Buddy Guy's Legends on Sunday. Learn more: https://sitcancer.org/funding/the-checkpoints-band

We're looking forward to attending 2024 ASCO Annual Meeting in Chicago from 5/31 - 6/4! You can visit us at Booth #27143. Learn more about the at ASCO conference event details: https://conferences.asco.org/am/attend

Interested in hearing more about our newly approved bladder cancer immunotherapy? Check out new interviews with Dr. Patrick Soon-Shiong and Dr. Bobby Reddy on the UroToday + GU OncToday podcast series with Ashish M. Kamat, MD, MBBS, Learn more here:

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast - ImmunityBio CULVER CITY, Calif., May 17, 2024 — ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company’s recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invas...

The FDA's green light for our first-in-class IL-15 receptor marks a new era in treating non–muscle-invasive bladder cancer (NMIBC). In this interview with Urology Times Dr. Patrick Soon-Shiong sheds light on the pivotal approval. Learn More:

Dr. Soon-Shiong discusses the FDA approval of N-803 in NMIBC “All this is very detailed immunology, I get that, but it sets the stage for what I consider the next evolution of immunotherapy,” says Patrick Soon-Shiong, MD.

In case you missed it: Dr. Pat Soon-Shiong participated in a fireside chat with Dr. Sam Chang at AUA2024. Learn more:

https://www.auadailynews.org/meeting-coverage/article/22908979/a-new-frontier-of-immunotherapy-for-bladder-cancer